These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 25855821)

  • 1. Paediatric pharmacokinetics: key considerations.
    Batchelor HK; Marriott JF
    Br J Clin Pharmacol; 2015 Mar; 79(3):395-404. PubMed ID: 25855821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model.
    Abduljalil K; Jamei M; Rostami-Hodjegan A; Johnson TN
    AAPS J; 2014 May; 16(3):568-76. PubMed ID: 24700271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics in infants and children. A reappraisal.
    Kearns GL; Reed MD
    Clin Pharmacokinet; 1989; 17 Suppl 1():29-67. PubMed ID: 2692939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups.
    Liu XI; van den Anker JN; Burckart GJ; Dallmann A
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S94-S107. PubMed ID: 34185902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in paediatric pharmacokinetics.
    Knibbe CA; Krekels EH; Danhof M
    Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):1-8. PubMed ID: 21117982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical moments in pharmacokinetics.
    Yamaoka K; Nakagawa T; Uno T
    J Pharmacokinet Biopharm; 1978 Dec; 6(6):547-58. PubMed ID: 731417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.
    Jones HM; Mayawala K; Poulin P
    AAPS J; 2013 Apr; 15(2):377-87. PubMed ID: 23269526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric oral biopharmaceutics: key considerations and current challenges.
    Batchelor HK; Fotaki N; Klein S
    Adv Drug Deliv Rev; 2014 Jun; 73():102-26. PubMed ID: 24189013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products - a PEARRL review.
    Guimarães M; Statelova M; Holm R; Reppas C; Symilllides M; Vertzoni M; Fotaki N
    J Pharm Pharmacol; 2019 Apr; 71(4):603-642. PubMed ID: 29971768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic (PBPK) modeling in children.
    Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B
    Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paediatric specific dosage forms: Patient and formulation considerations.
    Khan D; Kirby D; Bryson S; Shah M; Rahman Mohammed A
    Int J Pharm; 2022 Mar; 616():121501. PubMed ID: 35092832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic changes in critical illness.
    Boucher BA; Wood GC; Swanson JM
    Crit Care Clin; 2006 Apr; 22(2):255-71, vi. PubMed ID: 16677999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
    Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
    Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations.
    Gonzalez D; Sinha J
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1(Suppl 1):S175-S187. PubMed ID: 34185913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paediatric labelling requirements. Implications for pharmacokinetic studies.
    Wilson JT; Kearns GL; Murphy D; Yaffe SJ
    Clin Pharmacokinet; 1994 Apr; 26(4):308-25. PubMed ID: 8013163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A physiologically based pharmacokinetic model of the minipig: data compilation and model implementation.
    Suenderhauf C; Parrott N
    Pharm Res; 2013 Jan; 30(1):1-15. PubMed ID: 23179779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.